98%
921
2 minutes
20
To describe the frequency of and reasons for changes in healthcare utilization in those requiring ongoing treatment, and to assess characteristics associated with change, during the second wave of the pandemic. Corona Immunitas e-cohort study (age ≥20 years) participants completed monthly questionnaires. We compared participants reporting a change in healthcare utilization with those who did not using descriptive and bivariate statistics. We explored characteristics associated with the number of changes using negative binomial regression. The study included 3,190 participants from nine research sites. One-fifth reported requiring regular treatment. Among these, 14% reported a change in healthcare utilization, defined as events in which participants reported that they changed their ongoing treatment, irrespective of the reason. Reasons for change were medication changes and side-effects, specifically for hypertension, or pulmonary embolism treatment. Females were more likely to report changes [Incidence Rate Ratio (IRR) = 2.15, = 0.002]. Those with hypertension were least likely to report changes [IRR = 0.35, = 0.019]. Few of those requiring regular treatment reported changes in healthcare utilization. Continuity of care for females and chronic diseases besides hypertension must be emphasized.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469983 | PMC |
http://dx.doi.org/10.3389/ijph.2023.1606010 | DOI Listing |
J Orthop Res
September 2025
Department of Kinesiology, College of Health Sciences, University of Rhode Island, Kingston, Rhode Island, USA.
Arthroplasty surgery is a common and successful end-stage intervention for advanced osteoarthritis. Yet, postoperative outcomes vary significantly among patients, leading to a plethora of measures and associated measurement approaches to monitor patient outcomes. Traditional approaches rely heavily on patient-reported outcome measures (PROMs), which are widely used, but often lack sensitivity to detect function changes (e.
View Article and Find Full Text PDFBMC Health Serv Res
September 2025
Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Seebad 82/83, Rüdersdorf, 15562, Germany.
Background: Hypertension remains a critical public health issue in Germany, affecting millions of individuals. Mobile health applications (mHealth apps) offer promising solutions for improving patient outcomes and adherence in hypertension management. Despite their advantages in healthcare, the adoption of mHealth apps by general practitioners (GPs) in Germany remains limited to date.
View Article and Find Full Text PDFBMC Psychiatry
September 2025
Zentrum Isartal Am Kloster Schäftlarn, Schäftlarn, Germany.
Background: Patients with mental health conditions represent a significant concern in emergency departments, consistently ranking as the third or fourth most prevalent diagnoses during consultations. Globally, over the past two decades, there was a marked increase in such incidences, largely driven by a rise in nonurgent visits related to somatic complaints. However, the implications of these nonurgent visits for mental health patients remain unclear, and warrant further investigation.
View Article and Find Full Text PDFLeukemia
September 2025
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Pediatric acute myeloid leukemia (pAML) is a heterogeneous malignancy driven by diverse cytogenetic mutations. While identification of cytogenetic lesions improved risk stratification, prognostication remains inadequate with 30% of standard-risk patients experiencing relapse within 5 years. To deeply characterize pAML heterogeneity and identify poor outcome-associated blast cell profiles, we performed an analysis on 708,285 cells from 164 bone marrow biopsies of 95 patients and 11 healthy controls.
View Article and Find Full Text PDFThorax
September 2025
Usher Institute, The University of Edinburgh, Edinburgh, UK
Background: The long-acting monoclonal antibody nirsevimab and respiratory syncytial virus (RSV) vaccines became available for prevention of severe RSV-associated disease in 2023. While clinical trials showed good efficacy and safety, their restrictive inclusion criteria, small sample sizes and short follow-up limit generalisability. We aimed to summarise real-world evidence on the effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults.
View Article and Find Full Text PDF